About

Nutarniq is founded on the clinical research of Dr. Evan Lewis who has spent over 5 years researching nerve health, function and regeneration. He is leading the development of targeted nutritional therapy for chronic diseases and disease complication. These breakthrough nutrition options are now available in Canada and coming soon to countries around the world.

Dr. Lewis has focused his research on developing a nutrition therapy for neuropathy. His first clinical trials showed that after 1-year of therapy, people with diabetes and neuropathy showed 30% nerve regeneration. Diabetic neuropathy is the most prevalent and pervasive neuromuscular disease facing the world.  Diabetes is a global pandemic that affects over 415 million people and is expected to increase by 40% by 2040. Over 50% of all diabetics will develop diabetic neuropathy within 10-years of diabetes diagnosis.


Leadership

Dr. Evan Lewis

Dr. Evan Lewis PhD - CEO & Chief Scientist

 

Evan’s passion for nutritional science and human performance developed from his time training as an athlete on the Canadian Sailing Team. Evan completed his MSc at the University of Toronto, Faculty of Kinesiology where he investigated the hydration and energy requirements for Canadian Sailing Team athletes in preparation for the 2012 Olympics. He completed his PhD at the University of Toronto, Department of Nutritional Sciences, Faculty of Medicine where he investigated the effects of target nutritional supplementation with pro-nerve omega-3s to enhance nerve function in athletes. The positive results from this research lead to investigating the same solution as a targeted nutritional therapy for diabetic neuropathy.

 

Order Now

Advisory Board

Dr. Roger Mahabir LLD (Hon)
Roger Mahabir is Chairman of Tracker Networks Inc. He also serves as President of Technology Innovations Inc., and as Corporate Director and Audit Committee Chair for the Greater Toronto Airports Authority. He is a trained corporate director, having served on over 20 boards and advisory boards of NYSE, NASDAQ, TSX and Silicon Valley companies in the US, Canada and Europe. Roger is an active Angel investor, philanthropist, and mentor to entrepreneurial students and executives. 

 

Peter Ritchie CA CPA CBV

Peter Ritchie has over 20 years of executive experience in corporate governance, business strategy, financial reporting, enterprise risk management, financings and acquisitions. Currently, Peter is the Chief Financial Officer and Chief Risk Officer of Tracker Networks Inc.  Previously, Peter was the Chief Financial Officer of Community First Credit Union Limited and formerly held senior finance roles in Citigroup Inc.’s Canadian consumer finance and credit card businesses.

 

Dr. Vera Bril MD FRCPC
Dr. Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology. Her research interests have centred on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy. Her work has helped set the standards for electrophysiological investigations in the definition and evaluation of the progression of chronic polyneuropathies.

 

Dr. Bruce Perkins MD MPH FRCPC
Dr. Perkins is a Professor of Medicine (Endocrinology & Metabolism) at the University of Toronto and a Clinician Scientist at the Leadership Sinai Centre for Diabetes. His current research interests are diabetic neuropathy (nerve damage), diabetic kidney disease and strategies to help improve blood sugar control which includes the development of the artificial pancreas.